IP Library Patent Application 17113895
Patent Application
App. No. 17/113,895

ß- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ ß -CATENIN SIGNALING PATHWAY ACTIVATORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/113,895
Abstract

The present application discloses a compound which is which activates Wnt/β-catenin signaling and thus treats or prevents diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

Claims (11)

1 . A compound or pharmaceutically acceptable salt or prodrug thereof having the structure of formula I:

wherein R 1 is a substituted or unsubstituted heteroaryl, wherein the heteroaryl is selected from the group consisting of

with the proviso that a carbon atom is attached to the carbonyl;

R 2 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl and substituted or unsubstituted heterocyclyl, with the proviso that a carbon atom is attached to the carbonyl; and

R 3 , R 4 , R 5 and R 6 are independently selected from a group consisting of —C 1-9 alkyl, —C 1-9 alkylaryl and —C 1-9 alkylheteroaryl.

2 . The compound of claim 1 , wherein R 2 is selected from the group consisting of substituted or unsubstituted aryl,

3 . The compound of claim 1 , wherein R 3 and R 4 are H.

4 . The compound of claim 1 , having a structure of:

or pharmaceutically acceptable salt thereof.

5 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

6 . A method of treating alopecia or hair loss in a mammal, comprising topically administering to the mammal a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 12, 2026
From: TMF GROUP NEW YORK, LLC, NOT INDIVIDUALLY BUT SOLELY AS COLLATERAL AGENT
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 075109/0434 →
SECURITY INTEREST Recorded Sep 14, 2022
From: BIOSPLICE THERAPEUTICS, INC.
To: VICKERS VENTURE FUND VI PTE. LTD.; VICKERS VENTURE FUND VI (PLAN) PTE. LTD.; VICKERS-SPLICE CO-INVESTMENT LLC; MED-PATHWAYS II LIMITED
Reel/Frame 061433/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2021
From: SAMUMED, LLC
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 055694/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2020
From: KC, SUNIL KUMAR; WALLACE, DAVID MARK; HOOD, JOHN; BARROGA, CHARLENE F.
To: WINTHERIX LLC
Reel/Frame 054581/0367 →
CHANGE OF NAME Recorded Dec 8, 2020
From: WINTHERIX LLC
To: SAMUMED, LLC
Reel/Frame 054581/0436 →